Allogene Therapeutics (ALLO)
1.45
-0.01 (0.68%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13D/A Allogene Therapeutics, Filed by: TPG GP A, LLC
September 30, 2026 4:19 PM - SEC Filing
Allogene (ALLO) Reiterated at Market Outperform by Citizens on Progress in Autoimmune Diseases
September 15, 2026 5:29 AM - StreetInsider
Form 8-K Allogene Therapeutics, For: Aug 31
September 11, 2026 10:11 AM - SEC Filing
Allogene Therapeutics CFO Geoffrey Parker to retire in November
September 2, 2026 8:30 AM - StreetInsider
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 2, 2026 8:30 AM - StreetInsider
Allogene Therapeutics Announces Participation in September Investor Conference
August 31, 2026 8:30 AM - StreetInsider
Form 4 Allogene Therapeutics, For: Aug 21 Filed by: Douglas Earl Martin
August 25, 2026 4:43 PM - SEC Filing
Form 144 Allogene Therapeutics, Filed by: Douglas Earl Martin
August 21, 2026 7:27 PM - SEC Filing
Form EFFECT Allogene Therapeutics,
August 21, 2026 6:05 AM - SEC Filing
Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'
August 17, 2026 4:15 AM - StreetInsider
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.
August 14, 2026 4:34 PM - SEC Filing
Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c
August 12, 2026 4:40 PM - StreetInsider
Allogene Therapeutics (ALLO) files $500M mixed shelf
August 12, 2026 4:30 PM - StreetInsider
Form S-3 Allogene Therapeutics,
August 12, 2026 4:23 PM - SEC Filing
Form 10-Q Allogene Therapeutics, For: Jun 30
August 12, 2026 4:18 PM - SEC Filing
Form 8-K Allogene Therapeutics, For: Aug 12
August 12, 2026 4:13 PM - SEC Filing
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie
August 7, 2026 8:21 PM - SEC Filing
Form SCHEDULE 13G Allogene Therapeutics, Filed by: STATE STREET CORP
August 7, 2026 8:33 AM - SEC Filing
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 4, 2026 8:30 AM - StreetInsider
FDA grants RMAT and fast track status to Allogene's cema-cel
July 29, 2026 8:32 AM - StreetInsider
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026 8:30 AM - StreetInsider
Allogene's CAR T therapy shows 31% response rate in kidney cancer
July 15, 2026 8:30 AM - StreetInsider
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Sol
July 15, 2026 8:30 AM - StreetInsider
Full Article List
